References
- Stiller CA. Centralised treatment, entry to trials and survival. Br J Cancer 1994;70:352–62.
- Peppercorn JM, Weeks JC, Cook EF, Joffe S. Comparison of outcomes in cancer patients treated within and outside clinical trials: Conceptual framework and structured review. Lancet 2004;363:263–70.
- Braunholtz DA, Edwards SJ, Lilford RJ. Are randomized clinical trials good for us (in the short term)? Evidence for a “trial effect”.J Clin Epidemiol 2001;54:217–24.
- ECRI. Patients’ reasons for participation in clinical trials and effect of trial participation on patient outcomes. [cited 2010 Jun 26] Available from: https://www.ecri.org/Documents/Clinical_Trials_Patient_Guide_Evidence_Report.pdf;2002.
- Vist GE, Hagen KB, Devereaux PJ, Bryant D, Kristoffersen DT, Oxman AD. Outcomes of patients who participate in randomised controlled trials compared to similar patients receiving similar interventions who do not participate. Cochrane Database Syst Rev 2007:MR000009.
- Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): A phase III randomised controlled trial. Lancet 2007;370:135–42.
- Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, et al. Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study. Ann Oncol 2006;17:1523–8.
- Mekenkamp LJ, Koopman M, Teerenstra S, van Krieken JH, Mol L, Nagtegaal ID, et al. Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs. metachronous metastases. Br J Cancer 2010;103:159–64.
- Venderbosch S, de Wilt JH, Teerenstra S, Loosveld OJ, van Bochove A, Sinnige HA, et al. Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: Retrospective analysis of two randomized studies and a review of the literature. Ann Surg Oncol 2011; 18:3252–60.
- Sateren WB, Trimble EL, Abrams J, Brawley O, Breen N, Ford L, et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. JCO 2002;20:2109–17.
- Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. JCO 2005;23:3112–24.
- Rothwell PM. External validity of randomised controlled trials: “To whom do the results of this trial apply?”. Lancet 2005;365:82–93.
- Sorbye H, Pfeiffer P, Cavalli-Bjorkman N, Qvortrup C, Holsen, MH, Wentzel-Larsen T, et al. Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer 2009;115:4679–87.
- Power DG, Lichtman SM. Chemotherapy for the elderly patient with colorectal cancer. Cancer J 2010;16:241–52.
- Lara PN, Jr., Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, et al. Prospective evaluation of cancer clinical trial accrual patterns: Identifying potential barriers to enrollment. J Clin Oncol 2001;19:1728–33.